Diabetes Research
8 articles on Diabetes Research, researched and written by the Shotlee Editorial Team from primary sources.
Ozempic vs. Jardiance: Better Heart Protection for Diabetics with AFib
A new study compares GLP-1 and SGLT-2 inhibitors in patients with type 2 diabetes and atrial fibrillation, revealing significant differences in heart health outcomes.
7 min read
Beyond the Dose: Why Some GLP-1s Fall Short & What It Means
A groundbreaking Stanford study reveals a genetic reason why approximately 10% of individuals don't respond as expected to GLP-1 receptor agonists, impacting treatments for diabetes and weight loss.
7 min read
Beyond Ozempic: New Muscle-Burning Pill Reshaping Diabetes Care
A new experimental medication from Karolinska Institute targets muscle metabolism rather than appetite, offering a potential alternative to Ozempic and Wegovy with fewer side effects.
6 min read
GLP-1 Drugs Reduce Mortality Risk in Type 1 Diabetes
A recent study indicates that GLP-1 receptor agonists and incretin-based drugs may decrease mortality risk and hospital visits for adults with type 1 diabetes. Researchers compared outcomes in users versus non-users, finding significant benefits across BMI categories. Further long-term studies are needed to confirm safety and efficacy.
3 min read
What is 'Food Noise' and Why It's Gaining Attention with the Surge in GLP-1 Drugs?
Before starting Ozempic in spring 2023, Brenda Rogers hadn't recognized how 'food noise' drained her mental stamina. This term describes a constant preoccupation with food, tied to GLP-1 medications for diabetes and obesity. Experts explain its causes, how drugs alleviate it, and alternative approaches like therapy and diet adjustments.
4 min read
Anticipating Large Profits: Ozempic Patent Expiration Sparks Indian Pharma Generics Race
With the impending expiration of the Ozempic and Wegovy patents, Indian pharmaceutical giants are gearing up for a significant opportunity in the generics market. Surging obesity rates across India are fueling the demand for affordable weight-loss solutions.
7 min read
Mounjaro Weight-Loss Injection Now Top-Selling Drug in India
According to recent data, Mounjaro, a drug for obesity and diabetes developed by Eli Lilly, has emerged as India's top-selling pharmaceutical brand. The medication's sales have surpassed those of long-time market leader Augmentin.
3 min read
GLP-1 Breakthrough: Mazdutide Outperforms Semaglutide for Weight Loss & Diabetes
New research shows that Mazdutide may be superior to Semaglutide (Ozempic/Wegovy) for weight loss and improved blood sugar control. Learn about this exciting development and what it means for the future of diabetes and weight management.
3 min read